BioSpace News Archive

Drug Development

Karuna Pharma Closes on $42 Million Series A

Boston-based biotech company Karuna Pharmaceuticals completed a $42 million Series A financing. The round included the issuance of $22 million in shares upon conversion of debt into equity.

August 2, 2018
·
3 min read
·
Mark Terry
Drug Development

Karuna Completes $42 Million Series A Financing Round to Advance Selective Muscarinic Receptor Agonist Program into Phase 2 Study

Participants include ARCH Venture Partners, Wellcome Trust, PureTech Health, Steven Paul M.D., and other undisclosed investors

August 2, 2018
·
5 min read
Pharm Country

Applied DNA Sciences Reaches New Milestones in Therapeutic Contract Research and Contract Manufacturing of Linear DNA

Diagnostics Shipments, Vaccines Research, CAR T, and System Development bring in Requests for DNA

August 2, 2018
·
5 min read
Business

Acorda Provides Financial and Pipeline Update for Second Quarter 2018

Acorda Therapeutics, Inc. provided a financial and pipeline update for the quarter ended June 30, 2018.

August 2, 2018
·
10 min read
Business

DowDuPont Reports Second Quarter 2018 Results

GAAP EPS from Continuing Operations of $0.76; Adj. EPS Increases 41% to $1.37

August 2, 2018
·
45 min read
Drug Development

Investigator-initiated Phase II Clinical Study of Remetinostat Started in Patients With Basal Cell Carcinoma

edivir AB announced that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with basal cell carcinoma (BCC).

August 2, 2018
·
2 min read
Drug Development

First Patient Enrolled in Mallinckrodt’s Phase 2 Duchenne Muscular Dystrophy Trial

Trial to Assess Efficacy and Safety of Investigational Drug MNK-1411 in Patients with DMD

August 2, 2018
·
5 min read
Business

AmerisourceBergen Reports Fiscal 2018 Third Quarter Results

Revenues of $43.1 Billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year

August 2, 2018
·
43 min read
Business

Encision Reports First Quarter Fiscal Year 2019 Results

Encision Inc. announced financial results for its fiscal 2019 first quarter that ended June 30, 2018.

August 2, 2018
·
15 min read
Medicenna Provides Development Update on MDNA109 IL-2 Superkine Program

Promising Pre-Clinical Efficacy, Safety and Pharmacokinetics Shown by Long-Acting Fusions of MDNA109

August 2, 2018
·
5 min read